Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized investigator-blind study of 0.005% trifarotene cream vs 0.05% VAA cream in moderate facial acne
TCTR20210531008Phase 4Not yet recruiting
- Sponsor
- Galderma
- Start
- Aug 2021
- Modality
- Plant Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in acne vulgaris comparing 0.005% trifarotene cream with 0.05% VAA cream (2 arms). Planned start Aug 2021; status: not yet recruiting.
02
Drugs
trifarotenemistletoe lectin I
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on TCTR20210531008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210531008.